









市场行情
/
股票
/
nasdaq-omer
/

Omeros Corp

OMER

15.360USD

+6.610+75.54%

收盘 12/24, 13:00（美东）报价延迟15分钟

1.08B总市值

亏损市盈率 TTM



Omeros Corp

15.360

+6.610+75.54%

概览公司财务分析

概览

公司

财务

分析

关于 Omeros Corp 公司

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Omeros Corp简介



公司代码OMER

公司名称Omeros Corp

上市日期Oct 08, 2009

CEODemopulos (Gregory A)

员工数量202

证券类型Ordinary Share

年结日Oct 08

公司地址201 Elliott Avenue West

城市SEATTLE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编98119

电话12066765000

网址https://www.omeros.com/

公司代码OMER

上市日期Oct 08, 2009

CEODemopulos (Gregory A)

Omeros Corp公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Peter A. Demopulos, M.D.

Director

372.90K

Dr. Leroy E. Hood, M.D., Ph.D.

Independent Director

74.39K

Mr. Thomas J. Cable

Lead Independent Director

35.07K

Mr. Arnold C. Hanish, CPA

Independent Director

12.40K

Dr. Mariana N. Dimitrova, Ph.D.

Vice President - Chemistry, Manufacturing and Controls

Mr. Peter B. Cancelmo, J.D.

Vice President, General Counsel, Secretary

Dr. Thomas F. Bumol, Ph.D.

Independent Director

Dr. Catherine A. Melfi, Ph.D.

Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer

DR. Gregory A. Demopulos, M.D.

Chairman of the Board, President, Chief Executive Officer

Mr. David J. Borges

Chief Accounting Officer, Vice President - Finance, Treasurer

名称

名称/职务

职务

持股

持股变动

Dr. Peter A. Demopulos, M.D.

Director

372.90K

Dr. Leroy E. Hood, M.D., Ph.D.

Independent Director

74.39K

Mr. Thomas J. Cable

Lead Independent Director

35.07K

Mr. Arnold C. Hanish, CPA

Independent Director

12.40K

Dr. Mariana N. Dimitrova, Ph.D.

Vice President - Chemistry, Manufacturing and Controls

Mr. Peter B. Cancelmo, J.D.

Vice President, General Counsel, Secretary

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月5日周五

持股股东

股东类型

持股股东

占比

Ingalls & Snyder LLC (Asset Management)

5.79%

BlackRock Institutional Trust Company, N.A.

5.78%

The Vanguard Group, Inc.

4.72%

Stifel, Nicolaus & Company, Incorporated

2.56%

Morgan Stanley & Co. LLC

2.25%

其他

78.91%

持股股东

占比

Ingalls & Snyder LLC (Asset Management)

5.79%

BlackRock Institutional Trust Company, N.A.

5.78%

The Vanguard Group, Inc.

4.72%

Stifel, Nicolaus & Company, Incorporated

2.56%

Morgan Stanley & Co. LLC

2.25%

其他

78.91%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

16.88%

Investment Advisor

15.84%

Hedge Fund

7.54%

Research Firm

5.37%

Individual Investor

2.79%

Bank and Trust

0.86%

Insurance Company

0.10%

Pension Fund

0.07%

其他

50.55%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

243

29.83M

43.83%

+1.23M

2025Q2

255

30.16M

44.94%

-422.08K

2025Q1

263

30.38M

51.89%

-522.27K

2024Q4

256

29.32M

50.59%

-441.66K

2024Q3

242

27.89M

48.13%

-1.92M

2024Q2

248

27.65M

47.72%

-3.10M

2024Q1

269

28.11M

48.16%

-3.03M

2023Q4

275

27.52M

43.79%

-6.21M

2023Q3

299

30.25M

48.14%

-4.77M

2023Q2

303

29.52M

46.99%

+306.67K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Ingalls & Snyder LLC (Asset Management)

3.98M

5.85%

+5.10K

+0.13%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.69M

5.43%

-328.94K

-8.18%

Jun 30, 2025

The Vanguard Group, Inc.

3.28M

4.82%

+46.32K

+1.43%

Jun 30, 2025

Stifel, Nicolaus & Company, Incorporated

1.52M

2.24%

-33.76K

-2.17%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.09M

1.6%

+501.25K

+85.73%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.37M

2.01%

+739.00

+0.05%

Jun 30, 2025

Two Sigma Investments, LP

1.09M

1.61%

+971.88K

+802.28%

Jun 30, 2025

Demopulos (Gregory A. M.D.)

2.03M

2.98%

May 23, 2025

State Street Investment Management (US)

1.20M

1.76%

-156.01K

-11.50%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.94%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.05%

ProShares Ultra Nasdaq Biotechnology

0.05%

ProShares UltraPro Russell2000

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

Proshares Ultra Russell 2000

0.02%

ProShares Hedge Replication ETF

0.02%

iShares Russell 2000 Growth ETF

0.02%

Global X Russell 2000 ETF

0.02%

Invesco NASDAQ Future Gen 200 ETF

占比0.94%

iShares Micro-Cap ETF

占比0.09%

Invesco Nasdaq Biotechnology ETF

占比0.05%

ProShares Ultra Nasdaq Biotechnology

占比0.05%

ProShares UltraPro Russell2000

占比0.02%

Invesco RAFI US 1500 Small-Mid ETF

占比0.02%

Proshares Ultra Russell 2000

占比0.02%

ProShares Hedge Replication ETF

占比0.02%

iShares Russell 2000 Growth ETF

占比0.02%

Global X Russell 2000 ETF

占比0.02%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Omeros Corp的前五大股东是谁？



Omeros Corp 的前五大股东如下：
Ingalls & Snyder LLC (Asset Management)持有股份：3.98M，占总股份比例：5.85%。
BlackRock Institutional Trust Company, N.A.持有股份：3.69M，占总股份比例：5.43%。
The Vanguard Group, Inc.持有股份：3.28M，占总股份比例：4.82%。
Stifel, Nicolaus & Company, Incorporated持有股份：1.52M，占总股份比例：2.24%。
Morgan Stanley & Co. LLC持有股份：1.09M，占总股份比例：1.60%。